Filament Health Corp. (NEO: FH)

Market Cap	11.12M
Revenue (ttm)	2.16M
Net Income (ttm)	-4.15M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,085
Average Volume	40,748
Open	0.0400
Previous Close	0.0350
Day's Range	0.0400 - 0.0400
52-Week Range	0.0250 - 0.0900
Beta	1.00
RSI	56.02
Earnings Date	Mar 31, 2025

About Filament Health

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquarter...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Benjamin Lightburn
• Employees: 13
• Stock Exchange: Cboe Canada
• Ticker Symbol: FH

Financial Performance

In 2023, Filament Health's revenue was 2.13 million, an increase of 484.63% compared to the previous year's 364,500. Losses were -5.32 million, -67.68% less than in 2022.